Jocelyn H. Leu

1.7k total citations
45 papers, 1.1k citations indexed

About

Jocelyn H. Leu is a scholar working on Rheumatology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jocelyn H. Leu has authored 45 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Rheumatology, 14 papers in Genetics and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jocelyn H. Leu's work include Rheumatoid Arthritis Research and Therapies (17 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Jocelyn H. Leu is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (17 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Jocelyn H. Leu collaborates with scholars based in United States, Belgium and Netherlands. Jocelyn H. Leu's co-authors include Elizabeth C. Hsia, Diane D. Harrison, Yiying Zhou, Désirée van der Heijde, Kim Hung Lo, Lilianne Kim, Atul Deodhar, Arthur Kavanaugh, Michael B. Clark and Kim Campbell and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Jocelyn H. Leu

38 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jocelyn H. Leu United States	17	612	553	376	253	165	45	1.1k
Toru Yoshinari Japan	12	283 0.5×	181 0.3×	123 0.3×	91 0.4×	204 1.2×	20	855
Yichuan Xia United States	4	156 0.3×	637 1.2×	99 0.3×	165 0.7×	142 0.9×	6	892
Arno W. R. van Kuijk Netherlands	15	661 1.1×	562 1.0×	315 0.8×	27 0.1×	38 0.2×	29	1.1k
Stanley J. Marciniak United States	11	150 0.2×	373 0.7×	165 0.4×	45 0.2×	119 0.7×	19	773
Christopher Collins United States	14	523 0.9×	495 0.9×	50 0.1×	60 0.2×	41 0.2×	25	930
E. K. Li China	18	702 1.1×	427 0.8×	142 0.4×	43 0.2×	38 0.2×	23	934
Luca Járomi Hungary	14	91 0.1×	202 0.4×	74 0.2×	127 0.5×	115 0.7×	33	722
Hiroko Kanda Japan	18	273 0.4×	300 0.5×	76 0.2×	37 0.1×	74 0.4×	55	823
Bozena Möller Sweden	9	678 1.1×	471 0.9×	72 0.2×	90 0.4×	37 0.2×	12	962
Shizuyo Tsujimura Japan	16	539 0.9×	286 0.5×	87 0.2×	41 0.2×	53 0.3×	33	969

Countries citing papers authored by Jocelyn H. Leu

Since Specialization

Citations

This map shows the geographic impact of Jocelyn H. Leu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jocelyn H. Leu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jocelyn H. Leu more than expected).

Fields of papers citing papers by Jocelyn H. Leu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jocelyn H. Leu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jocelyn H. Leu. The network helps show where Jocelyn H. Leu may publish in the future.

Co-authorship network of co-authors of Jocelyn H. Leu

This figure shows the co-authorship network connecting the top 25 collaborators of Jocelyn H. Leu. A scholar is included among the top collaborators of Jocelyn H. Leu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jocelyn H. Leu. Jocelyn H. Leu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Crauwels, Herta, et al.. (2025). Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data. Pediatric Drugs. 28(1). 69–81.

Taylor, Peter C., Georg Schett, T. Huizinga, et al.. (2024). Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open. 10(2). e004278–e004278. 10 indexed citations

Zhou, Jie, Jocelyn H. Leu, Yuan Xiong, et al.. (2024). 232 Nipocalimab pharmacokinetic/pharmacodynamic and exposure-response modeling in pregnancies at risk for early-onset severe (EOS) HDFN. American Journal of Obstetrics and Gynecology. 230(1). S138–S138. 1 indexed citations

Leu, Jocelyn H., et al.. (2024). 503 Fetal and neonatal drug exposure following nipocalimab treatment in pregnant women at risk of EOS-HDFN. American Journal of Obstetrics and Gynecology. 230(1). S274–S275.

Leu, Jocelyn H., et al.. (2024). Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study. Frontiers in Neuroscience. 18. 1302714–1302714. 11 indexed citations

Taylor, Peter C., Fowzia Ibrahim, Bei Zhou, et al.. (2024). OA04 Efficacy and safety of nipocalimab in patients with moderate to severe active rheumatoid arthritis: the multicenter, randomised, double-blinded, placebo-controlled phase 2a IRIS-RA study. Lara D. Veeken. 63(Supplement_1). 2 indexed citations

Hubbard, Jesse J., Kim Campbell, Kathy L. Sivils, et al.. (2023). POS1130 DESIGNING OF A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN INHIBITOR, IN ADULTS WITH PRIMARY SJÖGREN'S SYNDROME. Annals of the Rheumatic Diseases. 82. 892–893. 1 indexed citations

Zuraw, Qing, Robert W. Hoffman, Terence Rooney, et al.. (2023). LP-195 Design of a Phase 2 study evaluating the efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus. SHILAP Revista de lepidopterología. A161.2–A161.

Zuraw, Qing, Robert W. Hoffman, Terence Rooney, et al.. (2023). AB0548 EFFICACY AND SAFETY OF NIPOCALIMAB IN ADULT PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: DESIGN OF A PHASE 2 STUDY. Annals of the Rheumatic Diseases. 82. 1472–1473.

10.

Lee, Jong Bong, Yijun Fan, Chuanpu Hu, et al.. (2022). Population Pharmacokinetic and Exposure–Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis. Clinical Therapeutics. 44(3). 457–464.e2. 1 indexed citations

11.

Husni, M. Elaine, Atul Deodhar, Sergio Schwartzman, et al.. (2022). Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Arthritis Research & Therapy. 24(1). 11 indexed citations

12.

Husni, M. Elaine, Arthur Kavanaugh, Frederick T. Murphy, et al.. (2019). Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis. Arthritis Care & Research. 72(6). 806–813. 16 indexed citations

13.

Reveille, John D., Atul Deodhar, Paul H. Caldron, et al.. (2019). Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study. The Journal of Rheumatology. 46(10). 1277–1283. 17 indexed citations

14.

Deodhar, Atul, M. Elaine Husni, Sergio Schwartzman, et al.. (2019). AB0385 INTEGRATED SAFETY ANALYSIS ACROSS PHASE 3 CLINICAL STUDIES INCLUDING THE CONTROLLED AND UNCONTROLLED PERIODS FOR INTRAVENOUS GOLIMUMAB IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS. Annals of the Rheumatic Diseases. 78. 1653–1654. 1 indexed citations

15.

Deodhar, Atul, Lianne S. Gensler, Joachim Sieper, et al.. (2018). Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis & Rheumatology. 71(2). 258–270. 238 indexed citations

16.

Wang, Weirong, et al.. (2018). Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFα Monoclonal Antibody. The AAPS Journal. 20(3). 63–63. 16 indexed citations

17.

Bingham, Clifton O., Alan M. Mendelsohn, Lilianne Kim, et al.. (2015). Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week‐112 Efficacy and Safety Results of the Open‐Label Long‐Term Extension of a Phase III, Double‐Blind, Randomized, Placebo‐Controlled Trial. Arthritis Care & Research. 67(12). 1627–1636. 15 indexed citations

18.

Kavanaugh, Arthur, Iain B. McInnes, Philip J. Mease, et al.. (2014). Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Annals of the Rheumatic Diseases. 73(9). 1689–1694. 106 indexed citations

19.

Papp, Kim, Jeffrey Crowley, J.‐P. Ortonne, et al.. (2010). Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. British Journal of Dermatology. 164(2). 434–441. 92 indexed citations

20.

Menon, Rajeev, et al.. (2007). Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. International Journal of Clinical Pharmacology and Therapeutics. 45(8). 448–454. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact